NCT06591910

Induction Therapy With Serplulimab Combined With Chemotherapy for Unresectable Stage III Non-small Cell Lung Cancer

Induction Therapy With Serplulimab Combined With Chemotherapy Followed by Local Therapy for Unresectable Stage III Non-small Cell Lung Cancer

• Status: Not Yet Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 50 (estimated)
• Sponsor: Shanghai Pulmonary Hospital, Shanghai, China · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

For unresectable stage III (8th TNM) non-small cell lung cancer, chemoradiotherpay plus immunotherapy is recommended by PACIFIC trial. However, it is unclear whether induction chemoimmunotherapy followed by surgery or radiotherapy can provide good survival for this population. This prospective observational study aims to investigate the efficacy and safety of the therapeutic regimen of chemoimmunotherapy plus surgery/radiotherapy.

Conditions

• Unresectable Stage III Non-small-cell Lung Cancer

Interventions

Type	Name	Description
DRUG	Chemoimmunotherapy	Induction Serplulimab combined with chemotherapy
PROCEDURE	Surgery	After induction chemoimmunotherapy, patients with tumors resectable after chemoimmunotherapy will receive surgical treatment in department of thoracic surgery.
RADIATION	Radiation	After induction chemoimmunotherapy, patients with tumors still unresectable will receive radiotherapy or other therapy.

Timeline

• Start date: 2024-09-20
• Primary completion: 2026-09-20
• Completion: 2030-09-20
• First posted: 2024-09-19
• Last updated: 2024-09-19